Mark James Litton Sells 25,107 Shares of Athira Pharma, Inc. (NASDAQ:ATHA) Stock

Athira Pharma, Inc. (NASDAQ:ATHA) CEO Mark James Litton sold 25,107 shares of Athira Pharma stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $0.56, for a total value of $14,059.92. Following the sale, the chief executive officer now directly owns 242,591 shares of the company’s stock, valued at approximately $135,850.96. This trade represents a 9.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.

Athira Pharma Stock Up 4.2 %

NASDAQ:ATHA traded up $0.02 on Friday, reaching $0.57. 127,376 shares of the company’s stock traded hands, compared to its average volume of 218,238. The stock has a 50-day simple moving average of $0.61 and a 200-day simple moving average of $1.52. Athira Pharma, Inc. has a 12 month low of $0.41 and a 12 month high of $4.30. The firm has a market cap of $22.16 million, a PE ratio of -0.20 and a beta of 2.99.

Athira Pharma (NASDAQ:ATHA) last posted its earnings results on Thursday, November 7th. The company reported ($0.75) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.05. On average, equities analysts anticipate that Athira Pharma, Inc. will post -2.35 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Separately, Mizuho lowered Athira Pharma from an “outperform” rating to a “neutral” rating and dropped their price target for the stock from $5.00 to $0.50 in a research note on Thursday, September 19th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of ATHA. GSA Capital Partners LLP grew its position in shares of Athira Pharma by 909.8% during the 3rd quarter. GSA Capital Partners LLP now owns 397,111 shares of the company’s stock worth $177,000 after buying an additional 357,787 shares in the last quarter. Forefront Analytics LLC increased its position in Athira Pharma by 126.0% during the 2nd quarter. Forefront Analytics LLC now owns 46,595 shares of the company’s stock valued at $123,000 after purchasing an additional 25,979 shares during the period. Dimensional Fund Advisors LP raised its holdings in shares of Athira Pharma by 25.5% in the 2nd quarter. Dimensional Fund Advisors LP now owns 550,353 shares of the company’s stock valued at $1,458,000 after purchasing an additional 111,759 shares in the last quarter. Invst LLC purchased a new stake in shares of Athira Pharma in the 2nd quarter worth approximately $68,000. Finally, XTX Topco Ltd bought a new position in shares of Athira Pharma during the second quarter valued at approximately $60,000. Institutional investors own 57.12% of the company’s stock.

About Athira Pharma

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.